Madrigal Pharmaceuticals (MDGL) Current Leases (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 15 years of Current Leases data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Current Leases rose 67.03% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 67.03% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 3.56% from the prior year.
• Current Leases for Q1 2026 stood at $1.7 million, up from $1.0 million in the prior quarter.
• Over the last five years, Current Leases for MDGL reached as high as $1.7 million in Q1 2026 and fell as low as $411000.0 in Q2 2023.
• Historically, Current Leases has averaged $798882.4 across 5 years, with a median of $760000.0 in 2022.
• Across the five-year window, Current Leases soared 118.11% in 2022 and plunged 53.24% in 2023, its largest moves.
• Year by year, Current Leases stood at $602000.0 in 2022, then slipped by 12.46% to $527000.0 in 2023, then soared by 86.53% to $983000.0 in 2024, then advanced by 3.56% to $1.0 million in 2025, then soared by 66.7% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.7 million in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.